Get the Stockscreener App
0.8097
24.36%
0.1586
After Hours:
.82
0.0103
+1.27%
Onconetix Inc stock is traded at $0.8097, with a volume of 29.78M.
It is up +24.36% in the last 24 hours and up +32.28% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
See More
Previous Close:
$0.6511
Open:
$0.878
24h Volume:
29.78M
Relative Volume:
5.96
Market Cap:
$6.72M
Revenue:
-
Net Income/Loss:
$-53.12M
P/E Ratio:
-0.00744
EPS:
-108.8
Net Cash Flow:
$-15.86M
1W Performance:
+110.31%
1M Performance:
+32.28%
6M Performance:
-87.32%
1Y Performance:
-89.61%
1-Day Range:
$0.76
$0.93
1-Week Range:
$0.364
$2.11
52-Week Range:
$0.3155
$21.40
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.8097 | 6.72M | 0 | -53.12M | -15.86M | -108.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Onconetix Inc Stock (ONCO) Latest News
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Onconetix files overdue quarterly report, addresses Nasdaq notice By Investing.com - Investing.com South Africa
Onconetix files overdue quarterly report, addresses Nasdaq notice - Investing.com
Onconetix, Inc. Announces Receipt of Notice from Nasdaq - GlobeNewswire
Onconetix Resolves Nasdaq Compliance Issue After Late Q3 Filing - StockTitan
ONCO stock touches 52-week low at $0.58 amid market challenges - Investing.com India
Onconetix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Onconetix Inc. (ONCO) reports earnings - Quartz
Onconetix amends forbearance agreement with Veru Inc. - Investing.com
ONCO Stock Hits 52-Week Low at $0.6 Amid Market Challenges - Investing.com Nigeria
ONCO stock touches 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
ONCO stock touches 52-week low at $0.99 amid market challenges - Investing.com
SEC Form 424B4 filed by Onconetix Inc. - Quantisnow
Zurcher Kantonalbank's Strategic Acquisition of Onconetix Inc Sh - GuruFocus.com
ONCO stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa
ONCO stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada
Onconetix, Inc. (NASDAQ:ONCO) Sees Large Decline in Short Interest - MarketBeat
Onconetix announces change in certifying accountant - Investing.com India
Onconetix announces change in certifying accountant By Investing.com - Investing.com South Africa
Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update - MarketBeat
Onconetix announces financing through $2M private placement - TipRanks
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C - The Bakersfield Californian
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewswire
Onconetix raises $2 million in private placement - Investing.com
Onconetix Secures Funding to Enhance Operations and Growth - TipRanks
Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewswire
Onconetix Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
What's Going On With Onconetix Shares Friday? - MSN
Investing in Onconetix Inc (ONCO) might be a great opportunity, but the stock is a bit overvalued - US Post News
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.20% - MSN
Onconetix (NASDAQ:ONCO) Stock Quotes, Forecast and News Summary - Benzinga
Onconetix shares go way up on Altos Ventures investment and stock split - Mugglehead
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Wall Street Today: US Stocks Rise On Soft Inflation Data As Investors Eye Further Fed Rate Cut, Chevron Corp Gains 2.46% - MENAFN.COM
Onconetix Inc (ONCO) Stock: From Low to High in 52 Weeks - The InvestChronicle
Crude Oil Rises; Onconetix Shares Spike Higher - Benzinga
Top US Gainer Onconetix Makes Retail ‘Extremely Bullish’ After VC Firm Boosts Stake - Barchart
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected - Benzinga
Wall Street today: US stocks rise on soft inflation data as investors eye further Fed rate cut, Chevron Corp gains 2.46% | Today News - Mint
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - MSN
China, quantum computers and new venture capital - RagingBull
Dow Surges Over 100 Points; Costco Earnings Top Views - Benzinga
China Evergrande's liquidators still in talks for stake sale in EV unit - Yahoo Finance
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
2.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):